Innovating.works Conecta tu I+D

Mostrando 1 al 20 de 42 resultados

CaReSyAn: Combatting the CardioRenal Syndrome towards an integrative Analysis to reduce cardiovascular burden... Bayer Pharma AG participó en un H2020: H2020-MSCA-ITN-2017 Successfully combatting a complex disease requires multi-disciplinary and methodically well-trained scientists. CaReSyAn strives to accompli...
2017-08-10 - 2021-12-31 | Financiado

IB4SD-TRISTAN: Imaging Biomarkers IBs for Safer Drugs Validation of Translational Imaging Methods in Drug Safety... Bayer Pharma AG participó en un H2020: H2020-JTI-IMI2-2015-07-two-stage 1.Our consortium has broad, deep experience of drug development and imaging biomarker (IB) validation. We are internationally recognized exp...
2017-03-10 - 2024-12-31 | Financiado

HARMONY: Healthcare Alliance for Resourceful Medicines Offensive against Neoplasms in HematologY Sofia ref.... Bayer Pharma AG participó en un H2020: H2020-JTI-IMI2-2015-06-two-stage Despite significant recent progress in the field of hematological malignancies (HMs), with increasing survival rates and improvement in qual...
2016-12-22 - 2023-06-30 | Financiado

BEAt-DKD: Biomarker Enterprise to Attack DKD Sofia ref. 115974 Bayer Pharma AG participó en un H2020: H2020-JTI-IMI2-2015-05-two-stage Diabetic kidney disease (DKD) is the leading cause of end stage renal disease (ESRD), and its global incidence and prevalence have reached e...
2016-12-20 - 2023-08-31 | Financiado

PREFER: Patient Preferences in benefit risk assessments during the drug life cycle Sofia ref. 115966 Bayer Pharma AG participó en un H2020: H2020-JTI-IMI2-2015-05-two-stage The PREFER project will deliver an overview and evaluation of preference elicitation methods to be applied in the entire drug life cycle, i....
2016-10-21 - 2022-05-31 | Financiado

ADAPT-SMART: Accelerated Development of Appropriate Patient Therapies a Sustainable Multi stakeholder Approach... Bayer Pharma AG participó en un H2020: H2020-JTI-IMI2-2015-04-two-stage-Master Progress in the life sciences and related technologies offer great potential for therapeutic benefits to patients in need. However, major ad...
2015-09-02 - 2018-04-30 | Financiado

ENLIGHT-TEN: European Network linking informatics and genomics of helper T cells Bayer Pharma AG participó en un H2020: H2020-MSCA-ITN-2015 ENLIGHT-TEN is a European Network Linking Informatics and Genomics of Helper T cells: our mission is to provide cross-disciplinary training...
2015-08-07 - 2019-09-30 | Financiado

IDEAS: Improving Design Evaluation and Analysis of early drug development Studies Bayer Pharma AG participó en un H2020: H2020-MSCA-ITN-2014 Drug development is a long and costly process which suffers from the major shortcoming that frequently failure is often only determined duri...
2014-12-16 - 2018-12-31 | Financiado

MAGICBULLET: Peptide Drug Conjugates for Targeted Delivery in Tumor Therapy Bayer Pharma AG participó en un H2020: H2020-MSCA-ITN-2014 Many tumor cells are characterized by the overexpression of certain antigens. Molecules that specifically recognize these structures are sui...
2014-12-05 - 2018-12-31 | Financiado

WEB-RADR: Recognising Adverse Drug Reactions Bayer Pharma AG participó en un FP6: WEB-RADR is a consortium of leading experts in pharmacovigilance from regulatory agencies, research, academia and patient support groups. To...
2014-09-01 - 2017-12-31 | Financiado

GETREAL: Incorporating real-life clinical data into drug development Bayer Pharma AG participó en un FP6: When a new medicine reaches the market, it is accompanied by an extensive data package that provides information about the safety and effica...
2013-10-01 - 2017-03-31 | Financiado

CHEM21: Chemical Manufacturing Methods for the 21st Century Pharmaceutical Industries Bayer Pharma AG participó en un FP6: CHEM21 is a project that will develop a broad based portfolio of sustainable technologies for green chemical intermediate manufacture aimed...
2012-10-01 - 2017-06-30 | Financiado

ABIRISK: Anti-Biopharmaceutical Immunization:Prediction and analysis of clinical relevance to minimize the ri... Bayer Pharma AG participó en un FP6: The ABIRISK project provides an integrated approach to the study of immunization against biopharmaceuticals, bringing together a unique pane...
2012-03-01 - 2018-02-28 | Financiado

EHR4CR: Electronic Health Record systems for Clinical Research Bayer Pharma AG participó en un FP6: Current medical needs, the growth of targeted therapies and personalized medicines, and escalating R&D costs result in formidable cost press...
2011-03-01 - 2016-02-29 | Financiado

ONCOTRACK: OncoTrack - Methods for systematic next generation oncology biomarker development Bayer Pharma AG tramitó un FP6: We propose here an exhaustive analysis of the genome, exome, methylome and transcriptome of primary tumours and metastases from patients wit...
2011-01-01 - 2016-12-31 | Financiado

ETOX: Integrating bioinformatics and chemoinformatics approaches for the development of expert systems all... Bayer Pharma AG participó en un FP6: The eTOX consortium proposes to develop innovative methodological strategies and novel software tools to better predict the toxicological pr...
2010-01-01 - 2016-12-31 | Financiado

SAFESCIMET: European Modular Education and Training Programme in Safety Sciences for Medicines Bayer Pharma AG participó en un FP6: Background:In current drug safety education and training in Europe, an integrative and translational approach is lacking. This shortfall has...
2010-01-01 - 2016-09-30 | Financiado

MARCAR: bioMARkers and molecular tumor classification for non-genotoxic CARcinogenesis Bayer Pharma AG participó en un FP6: MARCAR aims to establish reliable early markers and molecular classification of tumors in non genotoxic carcinogenesis, applying a mechanism...
2010-01-01 - 2015-06-30 | Financiado

EMTRAIN: European Medicines Research Training Network Bayer Pharma AG participó en un FP6: EMTRAIN is an essential element for the success of the IMI Education & Training (E&T) Call Topics in Europe (current and future). It will es...
2009-10-01 - 2016-09-30 | Financiado

EU2P: European programme in Pharmacovigilance and Pharmacoepidemiology Bayer Pharma AG participó en un FP6: The Eu2P training network in Pharmacovigilance and Pharmacoepidemiology will meet the needs of industry,regulatory authorities and academia...
2009-09-01 - 2016-06-30 | Financiado

BAYER